Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Completes Clarient Acquisition

NEW YORK (GenomeWeb) – NeoGenomics announced today it has completed its acquisition of Clarient from GE Healthcare's Life Sciences business.

The deal, which the cancer genetics testing provider first announced in October, has a purchase price of $80 million in cash, $110 million in preferred stock, and 15 million shares of NeoGenomics common stock, the company said in a statement. With the closing of the transaction, GE Healthcare now owns 32 percent of NeoGenomics. The company's board will also expand to include a new director from GE Healthcare, NeoGenomics added.

"We are very pleased to… begin to add Clarient's outstanding capabilities to our strong service offering," said NeoGenomics Chairman and CEO Douglas VanOort in a statement. "Clearly, the acquisition of Clarient is a major step forward in achieving our vision to become America's premier cancer testing laboratory."

Clarient, which is based in California and Texas, has about 415 employees and reported revenue of approximately $127 million in 2014, NeoGenomics said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.